Form 4: Syra Health Corp Director Ketan Paranjape Acquires Stock Options

Director Ketan Paranjape of Syra Health Corp acquired 19,303 stock options on November 14, 2024, under the company's 2022 Omnibus Equity Incentive Plan.

Summary

• Ketan Paranjape, a director at Syra Health Corp, acquired 19,303 stock options on November 14, 2024.
• These options were granted under the company's 2022 Omnibus Equity Incentive Plan.
• The options have an exercise price of $0.3683 per share.
• 25% of the options vested immediately upon grant, and the remaining options will vest in 12 equal monthly installments.
• The options expire on November 14, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction of stock options being granted to a director, which is generally viewed positively as it aligns interests. There is no indication of any negative sentiment.

Positives

• The acquisition of stock options by a director demonstrates confidence in the company's future performance.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Industry Context

This is a standard practice for incentivizing directors and aligning their interests with shareholders in publicly traded companies.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in publicly traded companies.
• The vesting schedule of 25% immediately and the remainder over 12 months is a typical vesting structure.
• The 10-year expiration period is also standard for stock options.

Stakeholder Impact

• The stock option grant may positively impact shareholder confidence by aligning director interests with company performance.

Key Dates

Keywords

stock options, equity incentive plan, director, insider trading, Syra Health Corp, vesting